SUSPECT ADVERSE REACTION REPORT I. REACTION INFORMATION 1. PATIENT INITIALS (first, last) PRIVACY OSTA RICA Day Month Year PRIVACY T + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
I. REACTION INFORMATION 1. PATIENT INITIALS (first, last) PRIVACY 1. PATIENT INITIALS (first, last) Day Month Pear PRIVACY 1. PATIENT INITIALS (first, last) Day Month Pear PRIVACY 2. DATE OF BIRTH 2a. AGE 3. SEX 3a. WEIGHT 4-6 REACTION ONSET APPROPRIATE TO ADVERSE REACTION PEB PRIVACY 4. SECRIBE REACTION(S) (including relevant tests/lab data) PATIENT DIED 7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
1. PATIENT INITIALS (first, last) PRIVACY 2. DATE OF BIRTH 54 Year Female 54 Years Female 68.00 kg 1. PATIENT ONSET APPROPRIATE TO ADVERSE REACTION PATIENT DIED 1.
1. PATIENT INITIALS (first, last) PRIVACY 2. DATE OF BIRTH Female 54 Year Female 54 Year Female 68.00 kg 1. PATIENT ONSET APPROPRIATE TO ADVERSE REACTION PATIENT DIED 1. PATIENT
1. PATIENT INITIALS (first, last) PRIVACY 2. DATE OF BIRTH Female 54 Year Female 54 Year Female 68.00 kg 1. PATIENT ONSET APPROPRIATE TO ADVERSE REACTION PATIENT DIED 1. PATIENT
(first, last) PRIVACY COSTA RICA Day Month PRIVACY Female 68.00 kg Day Month Year Semantic To Adverse Reaction PATIENT DIED 7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
PRIVACY PRIVACY PRIVACY Pears Female OU.00 RED REACTION 7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
I I I I NVOLVED OR
Severe pain on the right side (below the breast) [Pain]
desperate headache [Headache] Involved persistent or significant
DISABILITY OR INCAPACITY Case Description: ***This is an auto generated narrative***
☐ ☐ THREATENING
Study ID: 828652-My Healthy Journey
Study description: Trial title: This is a 40 weeks digital patient support program with focus on exercise, motivation, nutrition & maintaining (Continued on Additional Information Page)
II. SUSPECT DRUG(S) INFORMATION
14. SUSPECT DRUG(S) (include generic name) 20. DID REACTION
#1) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL {Lot # PP5L468; Exp.Dt. JUN-2026}
15. DAILY DOSE(S) #1) 3 mg, qd 16. ROUTE(S) OF ADMINISTRATION #1) Subcutaneous YES \[\subseteq NO \] NA
, , , , , , , , , , , , , , , , , , , ,
17. INDICATION(S) FOR USE 21. DID REACTION REAPPEAR AFTER REINTRODUCTION?
18. THERAPY DATES(from/to) 19. THERAPY DURATION
#1) 16-DEC-2024 / 17-FEB-2025
III. CONCOMITANT DRUG(S) AND HISTORY
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)
#1) VITAMIN C [ASCORBIC ACID] (VITAMIN C [ASCORBIC ACID]) Capsule ; 2023 / Ongoing
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)
Type of History / Notes Description Unknown to Ongoing Current Condition Menopause (Menopause)
Duration not reported
IV. MANUFACTURER INFORMATION
24a. NAME AND ADDRESS OF MANUFACTURER 26. REMARKS
Novo Nordisk A/S Lise Grimmeshave Vandtarnsvei 114
Soeborg, DK-2860 DENMARK Phone: +45 44448888
24b. MFR CONTROL NO. 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.
1461351
24c. DATE RECEIVED BY MANUFACTURER 24d. REPORT SOURCE STUDY LITERATURE
16-JUN-2025

Mfr. Control Number: 1461351

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

strategies (only for patients under Liraglutide 3.0 mg).

Patient's height: 153 cm.

Patient's weight: 68 kg.

Patient's BMI: 29.04865650.

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "Severe pain on the right side (below the breast)(Pain)" beginning on FEB-2025, "Nausea(Nausea)" with an unspecified onset date, "desperate headache(Headache)" with an unspecified onset date and concerned a 54 Years old Female patient who was treated with Saxenda (liraglutide 6 mg/mL) from 16-DEC-2024 to 17-FEB-2025 for "lose weight",

Dosage Regimens:

Saxenda: 16-DEC-2024 to 17-FEB-2025;

Current Condition: Menopause.

Concomitant medications included - VITAMIN C [ASCORBIC ACID].

Batch Numbers: Saxenda: PP5L468;

Action taken to Saxenda was reported as Product discontinued due to AE.

On 17-FEB-2025 the outcome for the event "Severe pain on the right side (below the breast)(Pain)" was Recovered.

The outcome for the event "Nausea(Nausea)" was Not Reported.

The outcome for the event "desperate headache(Headache)" was Not Reported.

Reporter's causality (Saxenda) -

Severe pain on the right side (below the breast)(Pain): Possible

Nausea(Nausea): Unknown

desperate headache(Headache): Unknown

Company's causality (Saxenda) -

Severe pain on the right side (below the breast)(Pain): Unlikely

Nausea(Nausea) : Possible

desperate headache(Headache): Possible